Bayer Aktiengesellschaft will close an administrative site in Robinson, Pa., impacting 569 jobs and 96 contractors amid broader restructuring efforts.
The German company's decision stems from a restructuring announced in November 2018, which includes divesting its animal health unit and Dr. Scholl's and Coppertone consumer product lines. CEO Werner Baumann said at the time that the restructuring will include cuts to about 1,200 jobs worldwide by 2021 to focus the company on its three core businesses in pharmaceuticals, consumer health and crop science. Baumann said the restructuring is unrelated to its $62.5 billion acquisition of Monsanto and litigation over the new unit's weedkiller Roundup.
Bayer said in a Jan. 15 statement provided to S&P Global Market Intelligence that the pending job cuts are part of this restructuring activity to improve the company's productivity and profitability in the U.S. Administrative functions will be consolidated, eliminating the Robinson facility, in an effort to provide better support to Bayer's St. Louis-based agriculture business and healthcare businesses headquartered in Whippany, N.J.
The company said it will close the site over a period of two years to allow for an orderly transition.